BLUE241220P5000
- 0.00
- 0.000.00%
bluebird bio Newsroom
Investor Optimism Abounds Bluebird Bio, Inc. (NASDAQ:BLUE) But Growth Is Lacking
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Bluebird Bio To Carry Out 1-for-20 Reverse Stock Split On December 13th, 2024
December 11th (Eastern Time) - $bluebird bio(BLUE.US)$ is about to implement a 1-for-20 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from December 13th, 2024
Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Express News | Bluebird bio Announces 1-for-20 Reverse Stock Split
Bluebird Bio Announces 1-for-20 Reverse Stock Split
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
Express News | CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026
Express News | Bluebird bio Inc - States Can Opt in to Agreement Until February 28, 2025
Express News | Bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (Cmmi) Cell and Gene Therapy Access Model
Express News | CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS
Bluebird Bio Shares Are Trading Lower After the FDA Announced an Investigation Into a Serious Risk of Hematologic Malignancy Following Skysona.
FDA Investigating Safety Risks of Bluebird's Skysona
FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)
Spotless Brands Expands Into Idaho and Oregon With Acquisitions of Bluebird Express Car Wash and Epic Shine Car Wash
Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $2